Core Viewpoint - Charles River Laboratories (CRL) reported quarterly earnings of $2.39 per share, exceeding the Zacks Consensus Estimate of $2.33 per share, but down from $2.66 per share a year ago [1] Financial Performance - The earnings surprise for the quarter was +2.51%, with the company having surpassed consensus EPS estimates in all four of the last quarters [2] - Revenues for the quarter were $994.23 million, surpassing the Zacks Consensus Estimate by 0.84%, compared to $1 billion in revenues a year ago [3] Stock Performance - Charles River shares have declined approximately 20.5% since the beginning of the year, contrasting with the S&P 500's zero return [4] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $2.52 for the coming quarter and $10.59 for the current fiscal year, alongside revenues of $992.69 million and $4.07 billion respectively [5][8] - The Zacks Rank for Charles River is currently 3 (Hold), indicating expected performance in line with the market in the near future [7] Industry Context - The Medical Services industry, to which Charles River belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [9]